Effect of Brewers yeast on blood glucose level and blood pressure in patients with type 2 diabetes mellitus

Effect of Brewers yeast on glycosylated hemoglobin, insulin resistance, insulin sensitivity and blood pressure in patients with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138807062513N1

Enrollment

Registered

2012-07-25

Start date

2009-11-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-insulin-dependent diabetes mellitus. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention group: receiving brewer's yeast tablet (two 300mg tablets three times daily, total 1800 mg) for 12 weeks. Intervention 2: control group: receiving placebo tablet (two 300

Treatment - Drugs

Placebo

Intervention group: receiving brewer's yeast tablet (two 300mg tablets three times daily, total 1800 mg) for 12 weeks

control group: receiving placebo tablet (two 300mg tablets three times daily, total 1800 mg) for 12 weeks

Eligibility

Sex/Gender

All

Age

35 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: History of at least 2 years clinically diagnosed type 2 diabetes mellitus; taking oral hypoglycemic drugs ; Fasting blood glucose at least more than 125 mg/dl; Not consuming brewers yeast during the last 3 months; Aged 35-55 years; Signing the informed consent form (attached). Exclusion criteria: History of hepatitis, cardiovascular, renal and Parkinson's diseases, gout and depression disorder, A record of angina pectoris, myocardial and cerebral infarction during the last year; History of infectious disease or common cold during the last 4 weeks; Regular consumption of anti-inflammatory drugs (steroid or non-steroid) or monoamine oxidase inhibitors; Insulin therapy; Consumption of brewers yeast or placebo less than 12 weeks; Any side effects due to supplementation; Change in diet or hypoglycemic drugs; Unwilling to continue taking supplementation.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting Blood Sugar. Timepoint: Baseline, After 12 weeks. Method of measurement: Blood Analysis: GOD / PAP method.;Glycosylated hemoglobin. Timepoint: Baseline, After 12 weeks. Method of measurement: Blood Analysis: boronate affinity assay.;HOMA-IR (homeostatic model assessment of insulin resistance). Timepoint: Baseline, After 12 weeks. Method of measurement: computed as fasting plasma glucose (mmol/L) × fasting serum insulin (mU/L) / 22.5.;QUICKI ( quantitative insulin sensitivity check index ). Timepoint: Baseline, After 12 weeks. Method of measurement: calculated as 1/ [log insulin (µIU/ml) + log glucose (mg/dl) ].;Systolic Blood pressure. Timepoint: Baseline, After 12 weeks. Method of measurement: Mercury sphygmomanometer.;Diastolic blood pressure. Timepoint: Baseline, After 12 weeks. Method of measurement: Mercury sphygmomanometer.	—

Measure

Time frame

Fasting Blood Sugar. Timepoint: Baseline, After 12 weeks. Method of measurement: Blood Analysis: GOD / PAP method.;Glycosylated hemoglobin. Timepoint: Baseline, After 12 weeks. Method of measurement: Blood Analysis: boronate affinity assay.;HOMA-IR (homeostatic model assessment of insulin resistance). Timepoint: Baseline, After 12 weeks. Method of measurement: computed as fasting plasma glucose (mmol/L) × fasting serum insulin (mU/L) / 22.5.;QUICKI ( quantitative insulin sensitivity check index ). Timepoint: Baseline, After 12 weeks. Method of measurement: calculated as 1/ [log insulin (µIU/ml) + log glucose (mg/dl) ].;Systolic Blood pressure. Timepoint: Baseline, After 12 weeks. Method of measurement: Mercury sphygmomanometer.;Diastolic blood pressure. Timepoint: Baseline, After 12 weeks. Method of measurement: Mercury sphygmomanometer.

—

Secondary

Measure	Time frame
Triglyceride. Timepoint: Baseline, After 12 weeks. Method of measurement: Blood Analysis: colorimetric method.;Total cholesterol. Timepoint: Baseline, After 12 weeks. Method of measurement: Blood Analysis: colorimetric method.;High Density Lipoprotein (HDL-c). Timepoint: Baseline, After 12 weeks. Method of measurement: Blood Analysis: Enzymatic method.;Low Density Lipoprotein (LDL-c). Timepoint: Baseline, After 12 weeks. Method of measurement: Blood Analysis: Enzymatic method.;Height. Timepoint: Baseline. Method of measurement: stadiometer (seca 206).;Weight. Timepoint: Baseline, After 12 weeks. Method of measurement: Digital scale (seca762).;Body Mass Index (BMI). Timepoint: Baseline, After 12 weeks. Method of measurement: Calculate.;Three days food intakes. Timepoint: Baseline, After 12 weeks. Method of measurement: 24-hour food recall.	—

Measure

Time frame

Triglyceride. Timepoint: Baseline, After 12 weeks. Method of measurement: Blood Analysis: colorimetric method.;Total cholesterol. Timepoint: Baseline, After 12 weeks. Method of measurement: Blood Analysis: colorimetric method.;High Density Lipoprotein (HDL-c). Timepoint: Baseline, After 12 weeks. Method of measurement: Blood Analysis: Enzymatic method.;Low Density Lipoprotein (LDL-c). Timepoint: Baseline, After 12 weeks. Method of measurement: Blood Analysis: Enzymatic method.;Height. Timepoint: Baseline. Method of measurement: stadiometer (seca 206).;Weight. Timepoint: Baseline, After 12 weeks. Method of measurement: Digital scale (seca762).;Body Mass Index (BMI). Timepoint: Baseline, After 12 weeks. Method of measurement: Calculate.;Three days food intakes. Timepoint: Baseline, After 12 weeks. Method of measurement: 24-hour food recall.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Abolghassem Djazayery

School of Public Health, Tehran University of Medical Sciences

djazayery@yahoo.com+98 21 6644 2095

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026